Philip Zimmermann
Philip Zimmermann is the CEO of Prevision Medicine, a spin-off from ETH Zürich focused on providing personalized cancer treatment analyses using an AI-driven approach. His company aims to simplify and expedite the process of analyzing patient samples, delivering rapid reports that rank medications based on their effectiveness for individual patients, thus fostering greater accessibility to personalized cancer treatment options.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 1 | 6.00 | 0.10% | +0% | 8,654,622 | 8,742 | $700,000 | 707$ |
| Totals | 1 | 8,654,622 | 8,742 | $700,000 | 707$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Philip Zimmermann is the CEO of Prevision Medicine, a spin-off that offers private analysis of cancer samples.
6